Education
About Us
Working with TipRanks
Follow Us
GNI Group Ltd. (DE:3G6)
FRANKFURT:3G6
3G6 Stock Chart & Stats
€12.40
€0.40(2.20%)
At close: 4:00 PM EST
€12.40
€0.40(2.20%)
Day’s Range― - ―
52-Week Range€8.80 - €26.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€722.03M
Enterprise Value€170.91B
Total Cash (Recent Filing)€22.78B
Total Debt (Recent Filing)€4.97B
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Feb 18, 2026EPS Estimate
1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding55,612,198
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-2.00
Price to Book (P/B)4.67
Price to Sales (P/S)7.21
P/FCF Ratio-46.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GNI Group News
3G6 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was €8.80 and its highest was €26.00 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is €722.03M.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is Feb 18, 2026 which is in 61 days.
How were GNI Group Ltd.’s earnings last quarter?
GNI Group Ltd. released its earnings results on Nov 14, 2025. The company reported €0.048 earnings per share for the quarter, missing the consensus estimate of €0.06 by -€0.013.
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Overvalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate is 1.25.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 55,612,198 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
GNI Group Ltd. reported an EPS of €0.048 in its last earnings report, missing expectations of €0.06. Following the earnings report the stock price went down -0.735%.
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in DE:3G6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GNI Group Ltd.
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
Technical Analysis
Options Prices
Currently, No data available
---